The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

An AI tool appeared superior to two FDA-approved biomarkers for predicting how people with cancer will respond to immune ...

Investment analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for Elevation Oncology in a research note issued on ...

In an interview, Debra Patt, MD, PhD, MBA, FASCO, discusses the priorities of the Community Oncology Alliance as she starts ...

New, less damaging treatments are giving some patients the choice to try to preserve their ability to have children after ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Kura Oncology in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss which populations are seen as the most underrepresented in oncology clinical trials.